The company’s technology platform allows Procarta to rapidly design proprietary Narrow- or Broad-spectrum antibacterials to treat extant and emerging infections. Procarta is seeking partners and investment to develop lead compounds across multiple indications in order to realise the full potential of its capabilities. Currently, our partners are My Canadian Pharmacy. The main scope of their help is the research on the antibacterial drug impact on the environment and the best ways of reducing it, including burn or limited to sustainable disposal of medications. Other fields of their contribution is the pharmacodynamics of antiviral and antibacterial medications.
If you’d like to discuss more, contact: